公开(公告)号：US12018020B2

公开(公告)日：2024-06-25

申请号：US17311560

申请日：2019-12-12

申请人： Intervet Inc.

发明人： Christophe Pierre Alain Chassaing ,  Xiaoling Jin ,  Rositza Iordanova Petrova ,  Richard J. Varsolona ,  Lorenzo Codan ,  Edward Cleator ,  Adrian Goodyear ,  Jonathan Simmons ,  Tanja Schweisel

IPC分类号： C07D405/14

CPC分类号： C07D405/14 ,  C07B2200/13

摘要： The present application relates to crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl) amino]pyrazole-4-carboxamide and processes for the preparation thereof. The compound is useful for the treatment of JAK-mediated diseases or conditions such as atopic dermatitis.

公开(公告)号：US20220227769A1

公开(公告)日：2022-07-21

申请号：US17628419

申请日：2020-07-24

申请人： Intervet Inc.

发明人： Rositza Iordanova Petrova ,  Gregory William York ,  Arush Pandya

IPC分类号： C07D471/10

摘要： The present disclosure encompasses a crystalline form of (5R,8S)-8-[[(1R)-1-[3,5bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione and processes for the preparation thereof.

公开(公告)号：US20220024902A1

公开(公告)日：2022-01-27

申请号：US17311560

申请日：2019-12-12

申请人： Intervet Inc.

发明人： Christophe Pierre Alain Chassaing ,  Xiaoling Jin ,  Rositza Iordanova Petrova ,  Richard J. Varsolona ,  Lorenzo Codan ,  Edward Cleator ,  Adrian Goodyear ,  Jonathan Simmons ,  Tanja Schweisel

IPC分类号： C07D405/14

摘要： The present application relates to crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl) amino]pyrazole-4-carboxamide and processes for the preparation thereof. The compound is useful for the treatment of JAK-mediated diseases or conditions such as atopic dermatitis.

公开(公告)号：US20210317077A1

公开(公告)日：2021-10-14

申请号：US17264417

申请日：2019-08-01

申请人： Intervet Inc.

发明人： Xiaoling Jin ,  Dirk Stueber ,  Cynthia Bazin ,  Rositza Iordanova Petrova ,  Christophe Pierre Alain Chassaing ,  Hans Peter Niedermann ,  Stephan Veit ,  Claudia Scheipers ,  Jochen Schoell

IPC分类号： C07C255/46

摘要： The present disclosure encompasses crystalline forms of N1-(1-cyanocyclopropyl)-N2-((1S)-1-{4′-[(1R-2,2-difluoro-1-hydroxyethyl]biphenyl-4-yl}-2,2,2-trifluoroethyl)-4-fluoro-L-leucinamide and processes for the preparation thereof.